|
US2018328952A1
|
|
Compounds and methods for the detection of methotrexate
|
|
US2008181903A1
|
|
Conjugate of natriuretic peptide and antibody constant region
|
|
WO2008070367A2
|
|
Mammalian cell-based immunoglobulin display libraries
|
|
CN101686971A
|
|
Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
|
|
EP2069478A2
|
|
Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
|
|
CN101534860A
|
|
Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
|
|
US2007224191A1
|
|
Methods of treatment of Ulcerative Colitis and Crohn's disease with anti-CD3 antibodies
|
|
HK1089189A1
|
|
Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
|
|
US2005276799A1
|
|
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US2005260212A1
|
|
Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
|
|
BRPI0509177A
|
|
use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
|
|
CA2545539A1
|
|
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
|
EP1675615A1
|
|
Treatment of respiratory diseases with anti-il-2 receptor antibodies
|
|
CN1856325A
|
|
Treatment of respiratory diseases with anti-IL-2 receptor antibodies
|
|
US7285268B2
|
|
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
|
|
US7361740B2
|
|
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
US7276372B2
|
|
Antibodies against GPR64 and uses thereof
|
|
AU2003298015A1
|
|
Methods of treatment of ulcerative colitis with anti-cd3 antibodies
|
|
US7276589B2
|
|
Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
|
|
US7217797B2
|
|
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
